chiauranib + albumin-paclitaxel + gemcitabine

**chiauranib + albumin-paclitaxel + gemcitabine** is a triple-drug combination therapy under clinical investigation for first-line treatment of locally advanced or metastatic pancreatic ductal adenocarcinoma. - **Chiauranib** is an orally administered, multi-target small molecule kinase inhibitor that selectively inhibits angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRα, c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R. It is designed to disrupt tumor angiogenesis, cell division, and inflammatory microenvironment processes through potent and selective inhibition[1]. - **Albumin-paclitaxel (nab-paclitaxel)** is a chemotherapy drug where paclitaxel is bound to human albumin nanoparticles. This enhances drug delivery to tumor cells by exploiting albumin's natural role in nutrient delivery while reducing hypersensitivity reactions associated with solvent-based paclitaxel[3]. - **Gemcitabine** is a nucleoside analog chemotherapeutic agent used widely as first-line therapy for pancreatic and other solid tumors; it inhibits DNA synthesis leading to cell death[3]. This combination is being studied to synergistically inhibit tumor growth and progression by targeting multiple pathways relevant to pancreatic cancer biology[1].

Brand names

Abraxane

Other names

nab-paclitaxelpaclitaxel protein-boundpaclitaxel albumin-boundalbumin-bound paclitaxelgemcitabine hydrochloride